摘要
Abstract
OBJECTIVE: To study the efficacy and the mechanism of Qianggan capsule in the treatment of nonalcoholic fatty liver fibrosis. METHODS: 104 patients with nonalcoholic fatty live fibrosis were randomly divided into treatment group (n=64) and control group (n=40). Both groups were given basic treatment of hepatoprotecuve drug for 6 months. Treatment group were treated with Qianggan capsule additionally. Hepatic fibrosis (HA, PcⅢ,CIV ,LN),TIMP-1, the hepatocyte CTGF,Collα2 mRNA and CTGF protein expression indicators of 2 groups before and after treatment were observed as well as liver biopsy. RESULTS: Hepatic fibrosis indicators and histopathology score were significant improved after experiment in Qianggan capsule group, and statistical results indicated significant difference between 2 groups(P<0.05). The expressions of CTGF,collα2 mRNA gene were inhibited and the expressions of CTGF protein were reduced after experiment in Qianggan capsule group, and statistical results indicated significant difference between 2 groups (P<0.05). CONCLUSION: Qianggan capsule can protecting hepatocyte,anti-fibrosis through cut down TIMP-1 level, and reduced CTGF,collo2 mRNA and the expressions of CTGF protein. It is a suitable drug in the treatment of nonalcoholic fatty liver fibrosis.关键词
强肝胶囊/非酒精性脂肪性肝病/肝纤维化/机制Key words
Qianggan capsule/ Nonalcoholic fatty liver disease/ Hepatic fibrosis/ Mechanism分类
医药卫生
